好色先生

好色先生

Explore the latest content from across our publications

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Thalamic nuclei volumes as markers of clinical disability and cognitive dysfunction in multiple sclerosis
Multiple Sclerosis
P5 - Poster Session 5 (5:30 PM-6:30 PM)
15-069

To investigate the associations between clinical disability and cognitive status with thalamic nuclei volumes in multiple sclerosis (MS).

Reduced thalamic volume has frequently been reported in MS and related to deficits including clinical disability and cognitive dysfunction. Although comprised of many nuclei with distinct functional roles, the thalamus is often treated as a single structure. The assessment of its individual components may allow for a more precise characterization of the associations between clinical deficits and thalamic volume.

MS patients were prospectively enrolled and scanned using 3T MRI. Participants underwent clinical and neuropsychological evaluation including: Expanded Disability Status Scale (EDSS), Nine-Hole Peg Test (9-HPT), and Timed 25-Foot Walk (T25-FW), Symbol Digit Modalities Test (SDMT), Brief Visuospatial Memory Test-Revised (BVMT-R), and California Verbal Learning Test–2nd edition (CVLT2), Anterior, intralaminar, lateral, medial, ventral, posterior nuclei (including the pulvinar), and total thalamus volumes were measured using FreeSurfer. Regression models assessed associations between thalamic volumes and clinical/neuropsychological outcomes, controlling for age, sex and education.

One hundred and eight MS patients were studied. Volumes of individual thalamic nuclei rather than total structural volume were retained in the final model for all regression analyses. Lateral nuclei volume explained incremental variance for EDSS (adjusted R2=.345, R2 change=.178, p<.0001) and SDMT (adjusted R2=.256, R2 change=.144, p<.0001). Anterior nuclei volume explained incremental variance for BVMT-R (adjusted R2=.191, R2 change=.089, p=.001) and CVLT2 (adjusted R2=.218, R2 change=.056, p=.007). Ventral nuclei volume explained incremental variance for T25-FW (adjusted R2=.132, R2 change=.107, p=.001). Posterior nuclei volume explained incremental variance for 9-HPT (adjusted R2=.071, R2 change=.062, p=.009). Results were similar, albeit with smaller R2 changes, when forcing total thalamic volume into the model except for 9-HPT where no nuclei were retained.

Our findings highlight the importance of individual thalamic nuclei volume in explaining disparate aspects of physical and cognitive impairment in MS.

Authors/Disclosures
Niels Bergsland (Buffalo Neuroimaging Analysis Center / State University of New York At Buffalo)
PRESENTER
Prof. Bergsland has nothing to disclose.
Ralph H. Benedict, PhD (University At Buffalo) Dr. Benedict has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Roche. Dr. Benedict has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Sanofi. Dr. Benedict has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Bristol Meyers Squibb. Dr. Benedict has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Immunic Therapeutics. Dr. Benedict has received intellectual property interests from a discovery or technology relating to health care.
Michael G. Dwyer III, MD, PhD (Buffalo Neurological Analysis Center) Dr. Dwyer has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Bristol Myers Squibb. Dr. Dwyer has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Keystone Heart, Ltd. Dr. Dwyer has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Novartis. The institution of Dr. Dwyer has received research support from Novartis. The institution of Dr. Dwyer has received research support from Keystone Heart, Ltd. The institution of Dr. Dwyer has received research support from Bristol Myers Squibb. The institution of Dr. Dwyer has received research support from Roche.
Tom Fuchs (Buffalo Neuroimaging Analysis Center) Mr. Fuchs has nothing to disclose.
Ferdinand Schweser, PhD (SUNY University At Buffalo) Dr. Schweser has received personal compensation in the range of $500-$4,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Elsevier.
Bianca Weinstock-Guttman, MD (Department of Neurology, University At Buffalo) Dr. Weinstock-Guttman has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Biogen. Dr. Weinstock-Guttman has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Genentech. Dr. Weinstock-Guttman has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Novartis . Dr. Weinstock-Guttman has received personal compensation in the range of $500-$4,999 for serving as a Consultant for EMD Serono. Dr. Weinstock-Guttman has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Abbvie. Dr. Weinstock-Guttman has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Genzyme &Sanofi. Dr. Weinstock-Guttman has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Janssen . Dr. Weinstock-Guttman has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Bayer. Dr. Weinstock-Guttman has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Horizon. Dr. Weinstock-Guttman has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Genentech. Dr. Weinstock-Guttman has received personal compensation in the range of $0-$499 for serving on a Scientific Advisory or Data Safety Monitoring board for Novartis. Dr. Weinstock-Guttman has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for Biogen. Dr. Weinstock-Guttman has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Janssen. Dr. Weinstock-Guttman has received personal compensation in the range of $0-$499 for serving as a Reviewer with NIH.
Robert Zivadinov, MD, PhD, FAAN (Buffalo Neuroimaging Analysis Center) The institution of Dr. Zivadinov has received personal compensation in the range of $500-$4,999 for serving as a Consultant for BMS. The institution of Dr. Zivadinov has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Omnicuris. The institution of Dr. Zivadinov has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Myrobalan. Dr. Zivadinov has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Sanofi. Dr. Zivadinov has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for EMD Serono. Dr. Zivadinov has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for Bristol Myers Squibb. The institution of Dr. Zivadinov has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for Biogen.